CluePoints, a leading provider of risk based monitoring (RBM) and data quality oversight solutions for clinical trials, has announced two new strategic appointments to strengthen its business development team.
Nick Borders and Rob Estrella join the CluePoints US team to support its impressive global business growth, allowing the company to increase its expanding client base across North America.
Nick Borders joins CluePoints having previously served as Associate Director of Business Development for Biomedical Systems, here he demonstrated key skills in managing both new and existing accounts, exceeding sales targets and creating strategic project plans.
With more than 9 years of experience as the Director of Business Development for TransPerfect, Rob Estrella has an extensive proven sales track record managing a life science and technology enterprise sales team resulting in 500+ new client relationships. Both will play key roles in capturing commercial opportunities across the US.
Following the opening of the new Wayne office in May and the continued year on year growth with global partnerships across Europe, North America and Asia-Pacific. CluePoints is leading the industry in the provision of its first-of-a-kind RBM and data quality oversight solutions to top ten biopharmaceutical companies as well as the small and mid-size sponsor and CRO sector.
The fact that CluePoints is entirely independent and is solely focused on this disruptive technology for central statistical monitoring means that the solution can provide the ultimate objective assessment of clinical trial and operational data, upholding the obligations of ICH E6 R2 and supporting FDA’s own approach to statistical interrogation of marketing submission data.
Patrick Hughes, Chief Commercial Officer, said: “As the industry is now fully embracing RbM, we are delighted to announce these new appointments to support our sustained growth. Their combined experience will be a tremendous asset to CluePoints at a time when we are developing quickly as a business.”
“They will both be instrumental in the company’s ongoing and future success, they will be a strong asset to the company and our clients alike.”
